Simtuzumab

Simtuzumab is an experimental drug that was under development by Gilead Sciences for the treatment of Idiopathic pulmonary fibrosis and Liver fibrosis. It is a monoclonal antibody that targets LOXL2, an enzyme that cross-links collagen and elastin in the extracellular matrix.

History

Simtuzumab was originally developed by Arresto Biosciences, which was acquired by Gilead Sciences in 2011. The drug entered Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis and liver fibrosis in 2012. However, the trials were discontinued in 2016 due to lack of efficacy.

Mechanism of Action

Simtuzumab works by binding to LOXL2, an enzyme that is involved in the cross-linking of collagen and elastin in the extracellular matrix. By inhibiting this enzyme, the drug is thought to reduce fibrosis.

Clinical Trials

Simtuzumab has been tested in several clinical trials for the treatment of various fibrotic diseases. However, the results have been disappointing. In 2016, Gilead Sciences announced that it was discontinuing the development of the drug due to lack of efficacy in Phase 2 trials.

Future Development

Despite the disappointing results, research into the role of LOXL2 in fibrosis continues. It is hoped that future drugs targeting this enzyme will be more effective.

See Also

• Gilead Sciences
• Idiopathic pulmonary fibrosis
• Liver fibrosis
• LOXL2
• Monoclonal antibody

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia